We previously demonstrated that tumor-specific type-1 T cells, which predominantly secrete IFN-γ, can efficiently traffic into CNS tumors and mediate effective therapeutic efficacy via type-1 chemokine CXCL10 (17, 18). This evidence concerns the gene CXCL10 and neoplasm.